Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Julia Kahl"'
Autor:
Jürgen Tchorz, Julia Kahl, Tim Jürgens, Sebastian Griepentrog, Hendrik Husstedt, Marlitt Frenz, Christina Fitschen
Publikováno v:
International Journal of Audiology. 61:34-45
This work presents the design and verification of a simplified measurement setup for wireless remote microphone systems (WRMSs), which has been incorporated into guidelines of the European Union of Hearing Aid Acousticians (EUHA).Three studies were c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bab404b1569ab335f49a9a654de44dd6
https://doi.org/10.1080/14992027.2021.1915505
https://doi.org/10.1080/14992027.2021.1915505
Autor:
Julia Kahl
Bachelorarbeit aus dem Jahr 2016 im Fachbereich Didaktik für das Fach Deutsch - Sonstiges, Note: 1,3, Universität zu Köln (IDSL), Sprache: Deutsch, Abstract: In der Ausarbeitung soll es um interkulturelles Erzählen gehen, welches anhand von Kirst
Autor:
Christopher Dietz-Fricke, Frank Tacke, Caroline Zöllner, Münevver Demir, Hartmut H. Schmidt, Christoph Schramm, Katharina Willuweit, Christian M. Lange, Sabine Weber, Gerald Denk, Christoph P. Berg, Julia M. Grottenthaler, Uta Merle, Alexander Olkus, Stefan Zeuzem, Kathrin Sprinzl, Thomas Berg, Florian van Bömmel, Johannes Wiegand, Toni Herta, Thomas Seufferlein, Eugen Zizer, Nektarios Dikopoulos, Robert Thimme, Christoph Neumann-Haefelin, Peter R. Galle, Martin Sprinzl, Ansgar W. Lohse, Julian Schulze zur Wiesch, Jan Kempski, Andreas Geier, Florian P. Reiter, Bernhard Schlevogt, Juliana Gödiker, Wolf Peter Hofmann, Peter Buggisch, Julia Kahlhöfer, Kerstin Port, Benjamin Maasoumy, Markus Cornberg, Heiner Wedemeyer, Katja Deterding
Publikováno v:
JHEP Reports, Vol 5, Iss 4, Pp 100686- (2023)
Background & Aims: Bulevirtide is a first-in-class entry inhibitor of hepatitis B surface antigen. In July 2020, bulevirtide was conditionally approved for the treatment of hepatitis D, the most severe form of viral hepatitis, which frequently causes
Externí odkaz:
https://doaj.org/article/25235c3dba9540059b007583dc50c8da
Autor:
Benjamin Maasoumy, Patrick Ingiliz, Christoph D. Spinner, Christiane Cordes, Hans-Jürgen Stellbrink, Julian Schulze zur Wiesch, Stephan M. Schneeweiß, Katja Deterding, Tobias Müller, Julia Kahlhöfer, Petra Dörge, Maria von Karpowitz, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg
Publikováno v:
JHEP Reports, Vol 5, Iss 3, Pp 100650- (2023)
Background & Aims: EASL guidelines recommend 8 weeks of treatment with sofosbuvir plus velpatasvir (SOF/VEL) for the treatment of acute or recently acquired HCV infection, but only 6- and 12-week data are available. Therefore, the aim of this study w
Externí odkaz:
https://doaj.org/article/612f548a04634195960c6a4eb99bc11d